BACKGROUND: Circulating chemerin, a novel adipokine linked to obesity, glucose tolerance and hyperlipidaemia, was recently reported to be increased in chronic kidney disease (CKD) patients. We explored possible links between chemerin and various clinical, nutritional and biochemical markers as well as its association with 5-year all-cause mortality. METHODS: Fasting plasma samples were obtained from 252 CKD Stage 5 patients [median age 56 years, male 61%, glomerular filtration rate (GFR) 7 mL/min] enrolled at the initiation of dialysis. Serum chemerin was measured using commercial ELISA. Chemerin levels were related to clinical status and biomarkers of inflammation, glucose and lipid metabolism and body composition (body mass index and total and truncal fat mass by dual-energy X-ray absorptiometry). Survival, censored for transplantation, was recorded for a follow-up time of 5 years. RESULTS: In univariate regression, circulating chemerin (119 ± 26 ng/mL) was positively correlated with cholesterol (ρ = 0.21; P = 0.001), triglycerides (ρ = 0.22; P = 0.0007), apolipoprotein B (ρ = 0.33; P < 0.0001), high-sensitivity C-reactive protein (ρ = 0.18; P = 0.006), white blood cell count (ρ = 0.23; P < 0.001), insulin (ρ = 0.18; P < 0.05) and homeostatic model assessment (HOMA) index (ρ = 0.17; P < 0.05), whereas we found a negative correlation with GFR (ρ = -0.28; P = 0.007), high-density lipoprotein cholesterol (ρ = -0.15; P < 0.05) and homocysteine (ρ = -0.25; P = 0.001). Moreover, a high chemerin predicted a better survival (log-rank χ(2) = 3.85; P < 0.05). Also, in a Cox model, adjustments for age, sex and CRP did not alter this finding (hazard ratio = 1.98 [95% confidence interval = 1.13-3.50], P = 0.01). However, adjusting for GFR made the model non-significant. CONCLUSIONS: We report that, in incident dialysis patients, an elevated chemerin is associated with a survival advantage despite its significant positive association with markers of inflammation and dyslipidaemia.
BACKGROUND: Circulating chemerin, a novel adipokine linked to obesity, glucose tolerance and hyperlipidaemia, was recently reported to be increased in chronic kidney disease (CKD) patients. We explored possible links between chemerin and various clinical, nutritional and biochemical markers as well as its association with 5-year all-cause mortality. METHODS: Fasting plasma samples were obtained from 252 CKD Stage 5 patients [median age 56 years, male 61%, glomerular filtration rate (GFR) 7 mL/min] enrolled at the initiation of dialysis. Serum chemerin was measured using commercial ELISA. Chemerin levels were related to clinical status and biomarkers of inflammation, glucose and lipid metabolism and body composition (body mass index and total and truncal fat mass by dual-energy X-ray absorptiometry). Survival, censored for transplantation, was recorded for a follow-up time of 5 years. RESULTS: In univariate regression, circulating chemerin (119 ± 26 ng/mL) was positively correlated with cholesterol (ρ = 0.21; P = 0.001), triglycerides (ρ = 0.22; P = 0.0007), apolipoprotein B (ρ = 0.33; P < 0.0001), high-sensitivity C-reactive protein (ρ = 0.18; P = 0.006), white blood cell count (ρ = 0.23; P < 0.001), insulin (ρ = 0.18; P < 0.05) and homeostatic model assessment (HOMA) index (ρ = 0.17; P < 0.05), whereas we found a negative correlation with GFR (ρ = -0.28; P = 0.007), high-density lipoprotein cholesterol (ρ = -0.15; P < 0.05) and homocysteine (ρ = -0.25; P = 0.001). Moreover, a high chemerin predicted a better survival (log-rank χ(2) = 3.85; P < 0.05). Also, in a Cox model, adjustments for age, sex and CRP did not alter this finding (hazard ratio = 1.98 [95% confidence interval = 1.13-3.50], P = 0.01). However, adjusting for GFR made the model non-significant. CONCLUSIONS: We report that, in incident dialysis patients, an elevated chemerin is associated with a survival advantage despite its significant positive association with markers of inflammation and dyslipidaemia.
Authors: Lei Zhao; Yasuto Yamaguchi; Shadi Sharif; Xiao-Yan Du; Jason J Song; David M Lee; Lawrence D Recht; William H Robinson; John Morser; Lawrence L K Leung Journal: J Biol Chem Date: 2011-09-19 Impact factor: 5.157
Authors: Jia Sun; Jonas Axelsson; Anna Machowska; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Karin Lindström; Peter Stenvinkel; Abdul Rashid Qureshi Journal: Clin J Am Soc Nephrol Date: 2016-06-08 Impact factor: 8.237
Authors: Simao Laranjeira; Daniel Regan-Komito; Asif J Iqbal; David R Greaves; Stephen J Payne; Piotr Orlowski Journal: Interface Focus Date: 2017-12-15 Impact factor: 3.906